Trial
NCT02512679
Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Children's Hospital Los Angeles
Collaborators
Lucile Packard Children's Hospital
Condition
Stem Cell Transplantation
Intervention
Cyclophosphamide Dose Level 1
Why stopped
Optimal dose obtained for engraftment and minimizing toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-27